Smith also points out that the focus on Dato-DXd has overshadowed AstraZeneca’s promising non-oncology pipeline, which is expected to deliver significant developments between 2025 and 2028.

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Symptom screening improved symptom scores among children with cancer compared with usual care, two randomized trials showed.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

AstraZeneca ( (AZN) ) has released its Q3 earnings. Here is a breakdown of the information AstraZeneca presented to its investors. AstraZeneca ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to ...